What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific batch of the prescription diabetes medication Semaglutide. This action was taken by Apollo Care, LLC, a company based in Columbia, Missouri. The product at the center of this recall is identified as SEMAGLUTIDE 0.9mg, which comes in a 1 mL Sterile Multi-Dose Vial. It is strictly for prescription use only and is designed specifically for subcutaneous injection, meaning it is intended to be injected into the fatty tissue just under the skin rather than into a muscle or vein.
To ensure you can accurately identify whether your medication is part of this recall, it is important to look at the specific details printed on the packaging and the vial itself. The brand name associated with this product is Apollo Care. The National Drug Code (NDC) for this particular item is 71170-810-01. This unique identifier is crucial because it distinguishes this specific formulation and manufacturer from other versions of Semaglutide that may be on the market. Additionally, you must check the lot number, which for this recall is AC-017131. The expiration date listed on the affected vials is August 30, 2026.
The distribution pattern for this recalled product indicates that it was sold nationwide within the United States. This means that patients across many different states may possess this specific lot of medication. The manufacturer's address is listed as 3801 Mojave Ct, Ste 102, Columbia, MO 65202. While the recall originates from Missouri, the scope of the distribution was national, affecting consumers everywhere in the U.S. who received this specific batch.
A Class II recall, as designated by the FDA, typically involves products that might cause temporary health problems or pose a slight threat of a serious nature, but are not expected to cause serious adverse health consequences or death. However, given that this is an injectable medication, any deviation from sterile standards is taken with significant seriousness. The recall was officially dated July 29, 2026. If you have been prescribed Semaglutide by Apollo Care and have vials matching the NDC and lot number above, it is essential to verify if they are part of this specific nationwide distribution that has now been flagged for potential safety issues.
The hazard, explained
When the U.S. Food and Drug Administration (FDA) issues a Class II recall for a pharmaceutical product like Apollo Care’s semaglutide, it is signaling that while the situation requires immediate attention, it is not typically an immediate life-threatening emergency on its own. However, the specific hazard identified in this recall—the presence of particulate matter within the sterile multi-dose vials—introduces serious and complex risks to patient safety that go beyond a simple manufacturing defect. To understand why this matters, we need to look at what actually happens inside your body when these tiny foreign particles enter your bloodstream or subcutaneous tissue.
The FDA’s investigation identified the contaminants as nylon/polyamide and silk/proteinaceous-type materials. In plain terms, this means that microscopic fragments of synthetic plastic and biological protein fibers have made their way into a solution that is supposed to be perfectly clear and sterile. Semaglutide is administered via subcutaneous injection, meaning it is delivered just under the skin. While the body is generally good at handling small amounts of material in the tissue layer where injections occur, introducing non-sterile or unexpected foreign bodies bypasses several of your immune system’s first-line defenses. These particles are not dissolved; they remain suspended in the liquid until you draw them into the injection device and push them into your body.
The physical mechanism of harm begins with the body’s inflammatory response. Your immune system recognizes these nylon and silk fragments as invaders or threats. It sends white blood cells to the site of the injection to engulf and isolate the foreign material. This process can cause localized reactions, such as increased redness, swelling, warmth, and pain at the injection site that is more severe than typical injection soreness. For some patients, this inflammation can lead to sterile abscesses, which are pockets of pus-like fluid filled with immune cells rather than bacteria, causing significant discomfort and potential tissue damage.
The risk escalates if these particles travel further. Although semaglutide is designed for local absorption, microscopic particulates can potentially enter the capillary networks near the injection site. Once in the bloodstream, these fragments can trigger a systemic inflammatory response. More critically, they pose a risk of embolization. If particles are large enough or numerous enough, they can physically block small blood vessels (capillaries) as they try to circulate through narrower parts of the body’s vascular system. This obstruction cuts off blood flow to tiny areas of tissue, potentially causing localized cell death or ischemia.
Furthermore, the "proteinaceous" nature of the silk-like material introduces an additional layer of complexity. Proteins are not inert; they can interact with your immune system in unpredictable ways. For individuals who have never been exposed to this specific type of protein before, the body may treat it as an allergen. This could lead to hypersensitivity reactions, ranging from mild hives and itching to more severe allergic responses. The combination of physical blockage, chemical irritation from the nylon/polyamide, and potential immune confusion from the silk-like proteins creates a "perfect storm" for adverse events that are difficult to predict or manage.
It is also important to consider the sterility aspect. While the recall facts specifically highlight particulate matter, any breach in the integrity of a sterile vial raises the specter of microbial contamination. If foreign particles entered the vial during manufacturing, it suggests that the aseptic processing environment may have been compromised. This means that alongside visible or invisible debris, there could be bacteria or fungi present, turning what might start as an inflammatory reaction into a serious infection.
In summary, the hazard here is not just about "dirty" medicine. It is about introducing solid, non-biodegradable, and potentially immunogenic foreign objects directly into your body’s delivery system. The body cannot simply flush these particles away easily; it must wall them off or fight against them, leading to pain, inflammation, potential tissue damage, and systemic immune stress. This is why the FDA classifies this as a significant recall event requiring immediate action from patients and healthcare providers.
Who is most at risk
The primary group affected by this recall consists of patients who have been prescribed semaglutide by Apollo Care, LLC for the management of type 2 diabetes or weight loss. Because this product is a prescription-only medication intended for subcutaneous injection, the individuals directly at risk are those actively using their multi-dose vials as directed by their healthcare providers. If you have received this specific medication from your pharmacy recently, you fall into the category of people who need to verify whether their supply is part of this recall.
While any patient injecting a contaminated product faces potential health complications, certain populations are particularly vulnerable to the consequences of particulate matter in injectable drugs. The hazard identified in this recall involves the presence of nylon/polyamide and silk/proteinaceous-type materials within the sterile vial. When these foreign particles enter the body through injection, they bypass the body’s natural filtration systems, such as the lungs or liver, which would normally trap larger impurities if the substance were ingested orally. Instead, these particles travel directly into the bloodstream or surrounding tissues, where they can trigger local inflammatory responses.
Elderly patients and those with compromised immune systems are at heightened risk. As we age, our bodies become less efficient at clearing foreign materials from the circulation, and our immune responses may be slower to react but more prone to excessive inflammation. For individuals with pre-existing conditions such as diabetes, which can already affect vascular health and wound healing, introducing particulate matter increases the likelihood of localized tissue damage, infection, or granuloma formation at the injection site. These are small areas of inflammation that can form when the body tries to wall off foreign material it cannot break down.
Additionally, patients who require frequent injections due to chronic conditions may accumulate these particles over time. Although this specific recall involves a single lot (AC-017131), the nature of multi-dose vials means that each use carries a risk if contamination is present throughout the container. Individuals with sensitive skin or those prone to allergic reactions may also experience heightened irritation, redness, or swelling at the injection site due to the proteinaceous components of the particulate matter. It is important to note that while serious systemic reactions are rare, the potential for local adverse events is significant enough to warrant immediate attention and medical consultation.
If you fall into any of these high-risk categories—particularly if you are elderly, immunocompromised, or have a history of injection site reactions—you should prioritize verifying your lot number and contacting your healthcare provider promptly. Do not wait for symptoms to appear, as early intervention can prevent minor irritation from developing into more serious complications.
How to tell if you have the recalled item
Locating a specific pharmaceutical product in your home medicine cabinet requires careful attention to detail, especially when the recall is based on a safety defect like particulate matter rather than expiration. Because this recall involves a sterile injectable drug, verifying the exact identity of your vial is critical. You must confirm that you possess the precise item listed in the FDA’s official notice. Do not rely solely on the name "Semaglutide," as many manufacturers produce this medication. Instead, you need to cross-reference several specific data points printed directly on the packaging and the glass vial itself.
First, look at the outer carton or the immediate label for the brand name. The recalled product is manufactured by Apollo Care, LLC. If your vial bears a different manufacturer’s name, it is not part of this specific recall action. Next, you must verify the strength and volume. The affected item is strictly SEMAGLUTIDE 0.9mg (0.9 mg/mL) contained in a 1 mL Sterile Multi-Dose Vial. It is designed for subcutaneous injection only. If your vial contains a different concentration or volume, it is excluded from this notice.
The most definitive way to identify the recalled units is by checking the National Drug Code (NDC) and the Lot Number printed on the label. You are looking for the following unique identifiers:
- NDC: 71170-810-01
- Lot Number: AC-017131
If your vial has a different lot number, even if the NDC matches, it is not part of this specific recall. Conversely, if the lot number matches but the NDC differs, it is also not included. Please check the expiration date as well; the recalled lot expires on 8/30/2026. However, note that the primary trigger for this recall is the presence of particulate matter (identified as nylon/polyamide and silk/proteinaceous-type material), so the expiration date alone does not determine if your item is safe to use. The physical defect is the key concern.
You should also review where you obtained the medication. This recall covers distribution nationwide within the United States, so geographic location does not rule out your vial being affected. The manufacturer’s address listed in the recall notice is 3801 Mojave Ct, Ste 102, Columbia, MO 65202, but this is the corporate address and may not appear on your personal prescription label. Focus entirely on the NDC, Lot Number, Brand Name, and Strength printed on your specific vial or box. If you are unsure, contact your pharmacist immediately with these details for confirmation.
What to do — step by step
If you have been prescribed or are currently using the recalled Apollo Care Semaglutide 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, your immediate priority is to ensure that this specific product does not enter your body. Because the FDA has identified the presence of particulate matter within these vials, continuing to use them poses a direct risk to your health. The recalled material consists of nylon/polyamide and silk/proteinaceous-type substances. While the recall facts provided do not explicitly state a formal remedy such as a mandatory return address or a specific refund process, the standard safety protocol for Class II drug recalls involving physical contamination is clear: you must cease use immediately.
- Stop using the medication right away. Do not administer any more doses from this vial, even if you believe it looks clear. Particulate matter can be microscopic and invisible to the naked eye. Once a drug is contaminated with foreign materials like nylon or proteinaceous debris, the sterility and safety of the entire multi-dose vial are compromised. It is not safe to try to filter out particles or to save the remaining liquid for later use.
- Identify your specific lot number. Check your vial carefully against the recall details. You are looking for NDC 71170-810-01 and Lot number AC-017131 with an expiration date of 8/30/2026. Confirming these exact identifiers ensures you are dealing with the recalled product and not a different, safe batch from Apollo Care.
- Contact your healthcare provider immediately. Since this is an Rx-only medication for subcutaneous injection, you need professional medical guidance on how to manage your treatment plan without interruption. Your doctor can help you determine if you need a replacement prescription from a different manufacturer or a different lot that has not been recalled. They may also advise you on monitoring for any adverse effects if you have already used some of the recalled product.
- Safely dispose of the product. Do not return the medication to a retail pharmacy unless explicitly instructed to do so by Apollo Care or the FDA, as the provided facts do not list a standard return address. Instead, follow your local community’s guidelines for pharmaceutical waste disposal. Many pharmacies and hospitals have take-back programs that accept contaminated or recalled medications safely. If you must dispose of it at home, mix the vial contents with an unpalatable substance like coffee grounds or cat litter in a sealed bag before throwing it in the trash to prevent accidental ingestion by children or pets.
- Report any adverse effects. If you have experienced any unusual symptoms after using this product, report them to your doctor and consider filing a report with the FDA’s MedWatch program. This helps health officials track potential incidents and ensures that any hidden risks are fully understood.
Please note that because the recall facts do not specify a remedy, you should monitor the official FDA website or contact Apollo Care directly for any updates on refunds or replacements. Your safety is the most important factor here, so erring on the side of caution and seeking professional medical advice is the best course of action.
Your refund, repair, or replacement options
When you receive a recall notice for a medication, the immediate question is often, "What happens next?" In this specific case involving Apollo Care, LLC’s recalled Semaglutide vials, the situation requires a bit of patience because the official FDA recall report does not currently list a specific remedy. This means there are no explicit instructions provided regarding whether you will receive a refund, a replacement vial, or a repair (which is not applicable to injectable drugs). While this absence of detail can feel unsettling, it is important to understand that a Class II recall indicates a hazard that is likely to cause temporary or medically reversible health problems. The primary goal here is safety, and the lack of stated financial remedy does not mean you are left without recourse; it simply means the standard process for resolving these issues is slightly different than for a defective toaster or a car part.
Because the recall documents do not specify who to contact for compensation or replacement, your first step must be to identify the source of your purchase. If you obtained this medication through a traditional brick-and-mortar pharmacy, that pharmacy is your primary point of contact. They hold the transaction records and often have established protocols for handling manufacturer recalls. You should call the pharmacist in charge at your local store, provide them with the NDC number (71170-810-01) and the lot number (AC-017131), and ask how they are processing returns for this specific batch. They can often facilitate a direct replacement with a different lot or process a refund to your original method of payment, depending on their inventory and company policy.
If you purchased this medication through a mail-order service or a specialty pharmacy, the process is similar but may involve a return shipping label. Contact their customer support line immediately. Do not attempt to ship the product back without explicit instructions, as hazardous materials or certain pharmaceuticals require specific handling procedures. These companies are typically more experienced in coordinating with manufacturers like Apollo Care, LLC, and they can guide you through their specific internal remedy process, which might include issuing a credit to your account rather than sending a physical replacement.
It is also worth noting that because the remedy is not stated in the public recall notice, there may be direct communication from Apollo Care, LLC to downstream distributors or healthcare providers that has not yet been fully publicized. If you are unsure how to proceed after contacting your pharmacy, you can reach out to Apollo Care, LLC directly at their listed address in Columbia, MO. However, for most consumers, the pharmacy is the most efficient path. Remember, the urgency here lies in stopping use of the product due to the particulate matter hazard, not in rushing through financial paperwork. Take a breath, contact your provider, and let them manage the logistics of the remedy while you focus on securing safe, alternative treatment if necessary.
- Check your receipt: Locate the original proof of purchase to speed up any refund or exchange process.
- Contact your pharmacy first: They are best equipped to handle manufacturer-specific recall logistics.
- Do not discard yet: Keep the vial and packaging intact until you have received instructions on how to return or dispose of it safely.
- Ask about alternatives: If you need ongoing treatment, ask your pharmacist if they can provide a different lot number from the same manufacturer or suggest an alternative medication immediately.
What can happen if you ignore it
When a pharmaceutical recall involves the presence of particulate matter in a sterile multi-dose vial, the risks are not merely theoretical; they are physical and immediate. The FDA has identified that the recalled SEMAGLUTIDE 0.9mg vials from Apollo Care, LLC contain foreign materials described as nylon/polyamide and silk/proteinaceous-type substances. If you continue to administer this medication without addressing the recall, you are essentially injecting microscopic debris directly into your body. This is not a minor inconvenience like taking a pill with a slightly off taste; it is a breach of the sterile barrier that protects your bloodstream and subcutaneous tissue from contamination.
The primary danger lies in what happens once these particles enter your system. Because SEMAGLUTIDE is administered via subcutaneous injection, any particulate matter introduced at this site can cause localized tissue reactions. You might experience increased pain, swelling, redness, or hardening at the injection site that does not resolve with standard care. These particles can act as a nidus for inflammation, triggering your immune system to attack the foreign material. In some cases, this can lead to sterile abscesses or chronic granulomas—lumps of inflamed tissue that form as the body tries to wall off the intruder. For someone managing a condition like type 2 diabetes or obesity with semaglutide, such complications can disrupt your treatment plan and cause unnecessary distress.
Beyond local tissue damage, there is the risk of systemic issues. While the particles described are likely too large to travel through capillaries to major organs, they can still enter the venous system if injected incorrectly or if the vial’s integrity is compromised further. More critically, the presence of foreign material often indicates a failure in the manufacturing or filtration process that could have allowed for microbial contamination as well. Even if bacteria are not present now, the breach in sterility increases the risk of infection. An injection site infection can escalate quickly into cellulitis, a serious skin and soft tissue infection that may require antibiotics or even surgical intervention.
Furthermore, ignoring the recall means you are using a product whose potency and safety cannot be guaranteed. The particulate matter may interfere with the drug’s delivery or absorption, potentially leading to erratic blood sugar levels or reduced therapeutic effect. You might think you are getting your prescribed dose, but the actual amount of active semaglutide reaching your system could be compromised. This uncertainty is dangerous for a medication that requires precise dosing to manage chronic conditions effectively. By continuing to use these vials, you are gambling with both your immediate physical safety and the long-term management of your health.
It is important to note that while no specific injuries or incidents were reported in the initial recall announcement, the potential for harm is inherent in the nature of the defect. In pharmaceutical manufacturing, particulate matter is a critical quality control failure precisely because it can lead to these severe outcomes. The absence of reported cases so far does not mean the risk is low; it often means that patients have not yet connected their symptoms to the product or have stopped using it for other reasons. Do not wait for a warning sign to appear. The safest course of action is to assume that any particle introduced into your body carries a non-zero risk of adverse reaction, and to eliminate that risk entirely by stopping use immediately.
Staying safe: broader tips
When it comes to prescription medications, particularly those delivered via multi-dose vials like semaglutide, your safety largely depends on how you handle the product after it leaves the pharmacy counter. While manufacturers and regulators work hard to ensure sterility during production, the integrity of a medication can be compromised once it is opened or stored incorrectly. One of the most critical aspects of preventing contamination is proper storage. Always follow the specific temperature guidelines provided by your pharmacist or the manufacturer’s labeling. Most multi-dose vials require refrigeration before opening, and some have strict limits on how long they can remain at room temperature after the first use. Keeping these medications within the correct temperature range prevents chemical degradation and helps maintain the sterile environment inside the vial.
Equally important is the technique you use when drawing doses. Because multi-dose vials are accessed multiple times, the risk of introducing particulate matter or bacteria increases with each puncture. Always wipe the rubber stopper with an alcohol swab before inserting your needle. Use a new, sterile needle for every single injection to prevent dragging surface contaminants back into the solution. If you ever notice cloudiness, discoloration, or visible particles in the vial—whether they look like tiny fibers, specks, or flakes—do not use it. Even if the expiration date is far in the future, a compromised seal or internal contamination renders the product unsafe. Trust your eyes; if it doesn’t look clear and consistent with its original state, it is not safe for injection.
Beyond individual handling practices, staying informed is your best defense against unseen risks. Prescription drugs are subject to ongoing monitoring by the FDA and other health agencies, but recalls can happen due to manufacturing errors, supply chain issues, or new safety data that emerges post-approval. To stay protected, regularly check the FDA’s official website for drug recall announcements and sign up for their email alert service. Additionally, keep a simple log of your medications, including lot numbers and expiration dates, either in a dedicated notebook or a secure digital note on your phone. This makes it much easier to identify if your specific batch is affected by a recall and allows you to act quickly rather than waiting for symptoms to appear.
Finally, communicate openly with your healthcare provider about any concerns regarding your medication’s appearance or effect. If you experience unexpected side effects after using a new vial, report them to your doctor and consider saving the unused portion of the vial along with its packaging until you can consult with a professional. These small, consistent habits—proper storage, sterile technique, vigilant inspection, and proactive monitoring—create a robust layer of protection that ensures your treatment remains both effective and safe throughout its use.